A strong commercial interest and rising application opportunities to boost the global CAS9 technology market in the forthcoming years. The market is projected to soar at a compound annual growth rate of 11.30% between 2018 and 2023. Emergence of genome editing or gene editing with engineered nucleases has taken genetic engineering to the next level. CAS9 technology is quickly gaining prominence as a genome editing tool. Advanced countries in North America and Europe are witnessing a faster uptake of the technology. Asia Pacific is also likely to present lucrative growth opportunities to market players during the review period.
This MRFR report offers a detailed analysis of the global CAS9 Technology Market. It also includes five-year revenue analysis, ending in 2023. The report starts with a market introduction where point such as scope of study, research objective and list of assumptions are discussed. This is followed by a through discussion on market dynamics. Next, an in-depth market segment and segment analysis is furnished. This report also includes a market competitive landscape, which covers some of the top companies operating in the global CAS9 technology market.
Cellecta, Inc., abm Inc., GenScript, CRISPR Therapeutic, Intellia Therapeutics, Inc., GE Healthcare, Takara Bio, Inc., AstraZeneca, PLC, Merck KGaA, Bio-Rad Laboratories, Inc., Danaher Corporation (Integrated DNA Technologies, Inc.), New England Biolabs, OriGene Technologies, Inc., Lonza Group, and Thermo Fisher Scientific.
Get Free Sample Copy of Report @ https://www.marketresearchfuture.com/sample_request/2064
The report offers insights into the leading market players and presents an assessment of their current market position. Company information with regards to revenue, segmental share, geographical income, SWOT, growth strategies, new product launch, M&A activities, and the latest R&D initiatives is also available in the report
Segmental analysis of the global CAS9 technology market has been conducted on the basis of product type, application, delivery method, and end user.
Based on product type, the market has been segmented into consumables and vectors. Of these, the vectors segment accounts for the largest share of the market. In 2017, the segment stood at a market valuation of USD 1,266.8 Mn and is likely exhibit a healthy growth rate during the forecast period. Some of popular vectors include CRISPR/Cas9 vectors, Cas9 only vectors, and T7 vectors. These genome editing tools find application in drug discovery and novel therapeutics for cancer hepatitis B, HIV, among others.
Based on application, the market has been segmented into genome engineering, disease models and in vitro genetic depletion. The genome engineering segment is expected to remain highly profitable in 2019 and beyond. In 2018, the segment reached a valuation in excess of USD 800 Mn. This is primarily owing to the increase of CRISPR/Cas9 based molecular mechanism in genome engineering.
Based on delivery method, the market has been segmented into physical delivery methods, viral delivery methods and non-viral delivery methods. The physical delivery method segment holds the dominant share of the market. The segment is expected to surpass a valuation of USD 1,700 Mn by the year 2023. There is a strong preference for physical delivery method owing to its high transfection efficiency.
Based on end user, the market has been segmented into biotechnology & pharmaceutical companies and academic & research institutes. The biotechnology & pharmaceutical companies segment accounts for the largest market share. With advances in genetic editing technology, CAS9 is drawing significant commercial interest.
On the basis region, the market has been segmented into Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas accounted for the largest market share in 2017 and is likely to remain high attractive throughout the assessment period. The market in Americas is expected to exhibit a CAGR of 11.52% from 2018 to 2023 and reach a valuation of over USD 1,300 Mn. Factors such as growing biotechnology industry and the faster adoption of innovative technologies in countries such the U.S. and Canada. A tremendous growth has been noticed in the biotechnology sector in the U.S. In addition, job opportunities in biotech has increased by 6.7% in 2018 as compared to 2015 in the country. Europe is the second largest market share for CAS9 technology. Rising CRISPR/CAS research activities in the pharmaceutical and biotechnology community in Europe is supporting the growth of the market.
Get Complete Report @ https://www.marketresearchfuture.com/reports/cas9-technology-market-2064
TABLE OF CONTENTS
1 Report Prologue
2 Market Introduction
2.1 Scope Of Study
2.2 Research Objective
2.3 List Of Assumptions
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4 Market Dynamics
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar